DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide—also catalogued under the pharmaceutical name emideltide—first isolated in the 1970s from the cerebral venous blood of sleeping rabbits. Early research explored whether it could modulate sleep architecture and stress-hormone signaling, but subsequent human evidence was limited and inconsistent. The FDA lists emideltide on its compounding safety-risk register, meaning no legitimate human-use pathway exists in the US.

Safety note. This article is educational and for personal recordkeeping only. It gives no dose, unit count, concentration, reconstitution, injection technique, vendor, cycle, or stacking instructions. Peptide decisions, especially gray-market or research-use products, belong with a licensed professional.

What is DSIP?

DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) found in trace concentrations in the central nervous system, pituitary, and peripheral organs. Its name comes from a 1974 discovery paper reporting sleep-induction effects in rabbits, though subsequent human research was limited and produced inconsistent findings. The FDA lists DSIP (emideltide) among bulk drug substances lacking sufficient safety data for proposed compounding use—no approved product or legitimate prescriber-supervised pathway exists for it in the United States.

That gap between “interesting animal research” and “safe for human use” is exactly where gray-market products operate. A beginner reading sleep-stack threads may see DSIP treated as an interchangeable option alongside melatonin or magnesium—it is not. The regulatory status means any vial you find is outside a supervised pathway. For a broader safety frame, read Research Peptide Safety Questions Before You Start.

What do people use DSIP for?

People most often mention DSIP for deep sleep, sleep architecture, recovery, stress resilience, and reducing reliance on other sleep aids. Those are community claims, not proof. The same claim can mean very different things depending on whether it comes from a clinical label, a small trial, an animal model, a vendor page, or a forum anecdote.

Use the claim as a filing label, not a conclusion. Write down the purpose in plain language: what outcome is being watched, what else changed at the same time, and what would count as a reason to stop and ask for care.

How do people discuss using DSIP?

Reported use usually means research-use listings and sleep-stack conversations that often sit beside melatonin, magnesium, glycine, or prescription sleep medicines. The useful part to record is context, not numbers: why it was considered, who reviewed it, what else was already in the stack, and what stop signs were discussed.

Do not copy online calculators, vendor protocols, or preparation walkthroughs into a personal plan. A peptide protocol log should preserve professional guidance and observations, not turn a social post into instructions.

What does the research say?

Older reviews describe DSIP research, but FDA safety material lists emideltide, or DSIP, as lacking safety information for proposed compounded-drug use.

A good research note separates mechanism, animal data, human trial data, approval status, and real-world anecdotes. When those buckets get mixed together, a peptide can look more proven than it is.

What should a beginner track?

Track sleep schedule, caffeine, alcohol, medication changes, wearable data if already used, daytime sleepiness, and whether symptoms call for a sleep clinician.

In Dosefi, keep the entry boring and complete: date, category, source type, professional guidance, symptoms, photos only when useful, and the question you want answered next. A clear log is not proof that the peptide works. It is a way to avoid rewriting the story after the fact.

What red flags matter most?

Insomnia can be medical, psychiatric, medication-related, or breathing-related. A peptide should not replace evaluation for sleep apnea, depression, withdrawal, or drug interactions.

Also pause when a product is sold only through anonymous vendors, when a blend hides individual ingredients, when the seller offers medical claims without medical oversight, or when the only evidence is a before-and-after post. Serious symptoms should be handled as health events, not as content to troubleshoot in comments.

Sources